Huya Bioscience International LLC;Shanghai Institute of Materia Medica, Chinese Academy of Sciences
发明人:
申请号：
EP10832058.1
公开号：
EP2501381B1
申请日:
2010.11.16
申请国别(地区):
EP
年份:
2017
代理人:
摘要：
Atrial fibrillation (AF) can be treated or prevented by administering to a subject who suffers from or is at risk of suffering from AF a composition comprised of an amount of an active agent, which is 4-methoxy-N-(3,5-bis-(1-pyrrolidinyl)-4-hydroxy benzyl) benzene sulfonamide (sulcardine) or a pharmaceutically acceptable salt thereof, such that the Cmax value the active agent in the subject is in the range from about 1 µM to about 20 µM.
